X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (15853) 15853
Magazine Article (10) 10
Book / eBook (3) 3
Book Chapter (2) 2
Conference Proceeding (1) 1
Dissertation (1) 1
Streaming Video (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (13498) 13498
female (7470) 7470
oncology (6903) 6903
cancer (6293) 6293
male (5983) 5983
animals (5745) 5745
middle aged (4660) 4660
aged (3884) 3884
adult (3470) 3470
chemotherapy (2974) 2974
mice (2744) 2744
research (2469) 2469
care and treatment (2296) 2296
tumors (2250) 2250
risk factors (1974) 1974
neoplasms - drug therapy (1822) 1822
medicine & public health (1819) 1819
health aspects (1797) 1797
breast cancer (1790) 1790
antineoplastic agents - adverse effects (1756) 1756
cell line, tumor (1720) 1720
treatment outcome (1703) 1703
apoptosis (1587) 1587
analysis (1512) 1512
antineoplastic combined chemotherapy protocols - adverse effects (1509) 1509
pharmacology & pharmacy (1504) 1504
expression (1503) 1503
metastasis (1391) 1391
antineoplastic combined chemotherapy protocols - therapeutic use (1387) 1387
antineoplastic agents - therapeutic use (1281) 1281
rats (1273) 1273
aged, 80 and over (1262) 1262
therapy (1254) 1254
breast neoplasms - drug therapy (1224) 1224
proteins (1148) 1148
gene expression (1143) 1143
biochemistry & molecular biology (1122) 1122
cell biology (1090) 1090
risk (1055) 1055
breast-cancer (1010) 1010
hematology (1008) 1008
cancer therapies (975) 975
cancer research (968) 968
drug therapy (944) 944
medicine (938) 938
genetic aspects (934) 934
research article (934) 934
prognosis (874) 874
prevention (870) 870
development and progression (863) 863
carcinoma (835) 835
dose-response relationship, drug (828) 828
neutropenia - chemically induced (825) 825
colorectal cancer (819) 819
oncology, experimental (818) 818
carcinogenesis (807) 807
multidisciplinary sciences (798) 798
clinical trials (793) 793
neoplasms, second primary - chemically induced (786) 786
disease models, animal (778) 778
studies (774) 774
time factors (767) 767
signal transduction (762) 762
retrospective studies (761) 761
hematology, oncology and palliative medicine (753) 753
cell proliferation (751) 751
medical research (751) 751
survival (737) 737
toxicology (730) 730
neoplasms - pathology (727) 727
toxicity (719) 719
cells (715) 715
gene expression regulation, neoplastic (715) 715
medicine, research & experimental (707) 707
antineoplastic agents - pharmacology (703) 703
review (703) 703
physiological aspects (698) 698
mutation (697) 697
follow-up studies (695) 695
adolescent (692) 692
breast neoplasms - pathology (683) 683
rodents (677) 677
neoplasms - metabolism (671) 671
lung cancer (665) 665
drug administration schedule (659) 659
kinases (649) 649
pathology (631) 631
antineoplastic agents - administration & dosage (629) 629
apoptosis - drug effects (628) 628
immunohistochemistry (624) 624
prostate cancer (624) 624
in-vitro (618) 618
antineoplastic agents (617) 617
patients (616) 616
surgery (611) 611
growth (610) 610
incidence (609) 609
disease-free survival (599) 599
in-vivo (599) 599
disease progression (595) 595
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (15770) 15770
Japanese (52) 52
French (31) 31
German (21) 21
Spanish (10) 10
Russian (5) 5
Hungarian (4) 4
Chinese (3) 3
Czech (3) 3
Italian (3) 3
Portuguese (3) 3
Arabic (1) 1
Croatian (1) 1
Dutch (1) 1
Hebrew (1) 1
Norwegian (1) 1
Polish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Lancet. Haematology, ISSN 2352-3026, 2016, Volume 3, Issue 5, pp. e217 - e227
...–cytarabine combination therapy (the MATRix regimen), followed by a second randomisation comparing consolidation with whole-brain radiotherapy or autologous stem cell transplantation in patients with primary CNS lymphoma... 
Hematology, Oncology and Palliative Medicine | 1ST-LINE TREATMENT | RESPONSE CRITERIA | GUIDELINES | NON-HODGKINS-LYMPHOMA | FOLLOW-UP | CENTRAL-NERVOUS-SYSTEM | WHOLE-BRAIN RADIOTHERAPY | HIGH-DOSE CHEMOTHERAPY | STEM-CELL TRANSPLANTATION | HEMATOLOGY | Follow-Up Studies | Cytarabine - therapeutic use | Humans | Lymphoma, B-Cell - therapy | Middle Aged | Male | Comparative Effectiveness Research | Hyperglycemia - chemically induced | Radiotherapy, Adjuvant - adverse effects | Hematopoietic Stem Cell Transplantation - adverse effects | Lymphoma, B-Cell - diagnostic imaging | Transplantation Conditioning - methods | Rituximab - adverse effects | Induction Chemotherapy - methods | Anemia - chemically induced | Central Nervous System Neoplasms - therapy | Thrombocytopenia - chemically induced | Mucositis - chemically induced | Magnetic Resonance Imaging | Methotrexate - adverse effects | Dexamethasone - therapeutic use | Radiotherapy, Adjuvant - methods | Transplantation, Autologous - adverse effects | Heart Injuries - chemically induced | Italy | Hematopoietic Stem Cell Transplantation - methods | Central Nervous System Neoplasms - mortality | Germany | Thiotepa - adverse effects | Thiotepa - therapeutic use | Thrombosis - chemically induced | Infections - chemically induced | Intraocular Lymphoma - therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Cytarabine - adverse effects | Methotrexate - therapeutic use | Rituximab - therapeutic use | Stroke - chemically induced | Optic Nerve Neoplasms - diagnostic imaging | Poisoning - epidemiology | Female | Remission Induction - methods | Transplantation Conditioning - adverse effects | Acute Kidney Injury - chemically induced | Neutropenia - chemically induced | Optic Nerve Neoplasms - therapy | Death, Sudden - epidemiology | Lymphoma, B-Cell - mortality | Intraocular Lymphoma - diagnostic imaging | Kaplan-Meier Estimate | Chemical and Drug Induced Liver Injury - epidemiology | Treatment Outcome | United Kingdom | Combined Modality Therapy - adverse effects | Switzerland | Induction Chemotherapy - adverse effects | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Central Nervous System Neoplasms - diagnostic imaging | Denmark | Combined Modality Therapy - methods | Neurotoxicity Syndromes - epidemiology | Gastrointestinal Diseases - chemically induced
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 2007, Volume 25, Issue 5, pp. 493 - 500
Journal Article
JNCI : Journal of the National Cancer Institute, ISSN 1460-2105, 2010, Volume 102, Issue 15, pp. 1114 - 1130
.... This success, however, is offset by the emergence of considerable long-term morbidity, including second malignant neoplasms, cardiovascular disease, neurotoxicity, nephrotoxicity, pulmonary toxicity... 
LONG-TERM SURVIVORS | CISPLATIN-INDUCED CYTOTOXICITY | ETOPOSIDE-INDUCED CYTOTOXICITY | PATIENTS RECEIVING CISPLATIN | QUALITY-OF-LIFE | RANDOMIZED CONTROLLED-TRIAL | GERM-CELL-CANCER | UMCG Approved | CORONARY-ARTERY-DISEASE | SINGLE NUCLEOTIDE POLYMORPHISMS | GENOME-WIDE ASSOCIATION | CARCINOMA-IN-SITU | BLEOMYCIN HYDROLASE GENE | ONCOLOGY | ATM SEQUENCE VARIANTS | RADIATION-INDUCED DAMAGE | Testicular Neoplasms - mortality | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Survivors - statistics & numerical data | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Fatigue - chemically induced | Pulmonary Fibrosis - genetics | Antineoplastic Agents - administration & dosage | Cardiovascular Diseases - genetics | Young Adult | Infertility, Male - genetics | Renal Insufficiency - chemically induced | Antineoplastic Agents - adverse effects | Employment | Adult | Paresthesia - chemically induced | Platinum Compounds - adverse effects | Renal Insufficiency - genetics | Genetic Predisposition to Disease | Genome-Wide Association Study | Neoplasm Recurrence, Local - prevention & control | Risk Assessment | Paresthesia - genetics | Survival Rate | Clinical Trials as Topic | Models, Statistical | Cognition - drug effects | Evidence-Based Medicine | Neoplasms, Second Primary - prevention & control | Testicular Neoplasms - drug therapy | Pulmonary Fibrosis - chemically induced | Quality of Life | Testicular Neoplasms - psychology | Cardiovascular Diseases - chemically induced | Platinum Compounds - administration & dosage | Infertility, Male - chemically induced | Population Surveillance | Cancer survivors | Care and treatment | Demographic aspects | Genetic aspects | Diagnosis | Research | Social aspects | Testicular cancer | Cancer | Index Medicus
Journal Article
The lancet oncology, ISSN 1470-2045, 2017, Volume 18, Issue 1, pp. 112 - 121
Summary Background Clonal haemopoiesis of indeterminate potential (CHIP) is an age-associated genetic event linked to increased risk of primary haematological... 
Hematology, Oncology and Palliative Medicine | ADJUVANT CHEMOTHERAPY | BREAST-CANCER | COLON-CANCER | VARIANTS | ONCOLOGY | FORMAT | SEQUENCE | MUTATIONS | LEUKEMIA | OUTCOMES | MYELODYSPLASTIC SYNDROMES | Clone Cells - drug effects | Prognosis | Follow-Up Studies | Humans | Leukemia, Myeloid, Acute - epidemiology | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Case-Control Studies | Incidence | Neoplasms, Second Primary - chemically induced | Myelodysplastic Syndromes - chemically induced | Aged, 80 and over | Female | Neoplasms, Second Primary - genetics | High-Throughput Nucleotide Sequencing - methods | Leukemia, Myeloid, Acute - chemically induced | Florida - epidemiology | Risk Factors | Hematopoiesis - genetics | Survival Rate | Mutation - genetics | Myelodysplastic Syndromes - epidemiology | Clone Cells - metabolism | Neoplasms - drug therapy | Neoplasms, Second Primary - diagnosis | Neoplasms, Second Primary - epidemiology | Myelodysplastic Syndromes - diagnosis | Clone Cells - pathology | Leukemia, Myeloid, Acute - diagnosis | Aged | Biomarkers, Tumor - genetics | Myelodysplastic Syndromes - genetics | Neoplasm Staging | Neoplasms - pathology | Leukemia, Myeloid, Acute - genetics | Care and treatment | Chemotherapy | Oncology, Experimental | Mortality | Aged patients | Research | Epidemiology | Cancer | Development and progression
Journal Article
Journal Article
British journal of haematology, ISSN 0007-1048, 2017, Volume 178, Issue 1, pp. 72 - 80
Journal Article
Journal Article
The lancet oncology, ISSN 1470-2045, 2010, Volume 11, Issue 7, pp. 670 - 678
Summary Since the introduction of multi-agent chemotherapy for osteosarcoma over 30 years ago, overall survival has exceeded 50%. A clear understanding of the... 
Hematology, Oncology and Palliative Medicine | SECONDARY MALIGNANCIES | DEXRAZOXANE-ASSOCIATED RISK | NEOADJUVANT CHEMOTHERAPY | ONCOLOGY | HIGH-DOSE METHOTREXATE | ACUTE LYMPHOBLASTIC-LEUKEMIA | PEDIATRIC-ONCOLOGY-GROUP | TERM-FOLLOW-UP | IFOSFAMIDE-INDUCED NEPHROTOXICITY | 2ND MALIGNANT NEOPLASMS | CISPLATIN NEPHROTOXICITY | Osteosarcoma - drug therapy | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Heart Diseases - prevention & control | Cisplatin - administration & dosage | Neoplasms, Second Primary - chemically induced | Kidney Diseases - chemically induced | Bone Neoplasms - drug therapy | Heart Diseases - chemically induced | Hearing Loss - chemically induced | Doxorubicin - administration & dosage | Antidotes | Kidney Diseases - prevention & control | Infertility - prevention & control | Ifosfamide - adverse effects | Survivors | Neurotoxicity Syndromes - prevention & control | Neoplasms, Second Primary - prevention & control | Neurotoxicity Syndromes - etiology | Methotrexate - adverse effects | Ifosfamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Cisplatin - adverse effects | Methotrexate - administration & dosage | Doxorubicin - adverse effects | Hearing Loss - prevention & control | Infertility - chemically induced | Osteosarcoma | Chemotherapy | Cancer | Index Medicus | Heart | Complications | Ifosfamide | Etoposide | Cytotoxicity | Drug development | Doxorubicin | Survival | Cisplatin | Hearing loss | Neurotoxicity | Infertility | Methotrexate | Acute toxicity
Journal Article
Blood, ISSN 0006-4971, 2009, Volume 113, Issue 16, pp. 3673 - 3678
We report the long-term outcome of a multicenter, prospective study examining fludarabine and rituximab in Waldenstrom macroglobulinemia (WM). WM patients with... 
MULTIPLE-MYELOMA | PROGNOSTIC FACTORS | MANTLE-CELL LYMPHOMA | TREATMENT RECOMMENDATIONS | CHRONIC LYMPHOCYTIC-LEUKEMIA | PHASE-II | FOLLICULAR LYMPHOMA | LOW-GRADE | HEMATOLOGY | 3RD INTERNATIONAL WORKSHOP | COOPERATIVE-ONCOLOGY-GROUP | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prospective Studies | Follow-Up Studies | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Neoplasms, Second Primary - mortality | Waldenstrom Macroglobulinemia - diet therapy | Pneumonia - mortality | Time Factors | Neoplasms, Second Primary - chemically induced | Pneumonia - chemically induced | Myelodysplastic Syndromes - chemically induced | Neutropenia - mortality | Female | Waldenstrom Macroglobulinemia - mortality | Leukemia, Myeloid, Acute - chemically induced | Neutropenia - chemically induced | Antibodies, Monoclonal, Murine-Derived | Vidarabine - adverse effects | Rituximab | Survival Rate | Thrombocytopenia - chemically induced | Vidarabine - analogs & derivatives | Leukemia, Myeloid, Acute - mortality | Disease-Free Survival | Antibodies, Monoclonal - administration & dosage | Myelodysplastic Syndromes - mortality | Thrombocytopenia - mortality | Aged | Vidarabine - administration & dosage | Index Medicus | Abridged Index Medicus | Clinical Trials and Observations
Journal Article
Leukemia & Lymphoma, ISSN 1029-2403, 2014, Volume 56, Issue 6, pp. 1643 - 1650
Journal Article